Abstract Background Coronavirus disease 2019 (COVID-19) prompted an unprecedented global vaccine development response and accelerated regulatory pathways for clinical vaccine development. Despite t...
<p><strong>Tác giả:</strong> Érique José Farias Peixoto de Miranda, José Alfredo Sousa Moreira, Ricardo Sobhie Diaz, Carlos Alexandre Antunes de Brito, Marcos Carvalho Borges, Fabio Eudes Leal, Luis Augusto Tavares Russo, Fernanda Castro Boulos, Maria Aparecida Alves Leite dos Santos Almeida, Márcia Cristina Oliveira da Rocha, Karina Takesaki Miyaji, João Ítalo Dias França, Marcos Alves de Lima, Lucas Ragiotto, Rama Raghunandan, Adolfo García‐Sastre, Weina Sun, Peter Palese, Florian Krammer, Cássia G. Terrassani Silveira, Carolina Argondizo Correia, Mariana Prado Marmorato, Mateus Vailant Thomazella, Esper Georges Kallas</p>
<p>Abstract Background Coronavirus disease 2019 (COVID-19) prompted an unprecedented global vaccine development response and accelerated regulatory pathways for clinical vaccine development. Despite the end of the public health emergency, sustained preparedness, including scalable and affordable vaccine platforms remains essential. Methods This is a non-inferiority, multicenter, randomized, double-blind and active-controlled Phase II clinical trial, to evaluate the immunogenicity and safety of a...</p>
<p>📄 DOI: <a href="https://doi.org/https://doi.org/10.1038/s41598-026-74408-4" target="_blank" rel="noopener">https://doi.org/10.1038/s41598-026-74408-4</a></p>
<p>📖 <a href="https://doi.org/https://doi.org/10.1038/s41598-026-74408-4" target="_blank" rel="noopener">Xem bài báo đầy đủ</a></p>
Bài viết được biên soạn lại bởi LIFVietnam. Nguồn tham khảo: OpenAlex
